Coroner's Finding: TAYLOR Michael Jason
Deceased
Michael Jason Taylor
Demographics
27y, male
Date of death
2000-02-26
Finding date
2004-04-20
Cause of death
Not determined; olanzapine toxicity suspected but regarded by expert evidence as unconvincing explanation; possible drug interactions, undetected substance, or undemonstrated cardiac/neurological mechanism
AI-generated summary
Michael Jason Taylor, aged 27, died on 26 February 2000 while detained at Glenside Hospital under the Mental Health Act 1993. He was a patient with chronic schizophrenia, borderline intelligence, and a history of drug-seeking behaviour. On 5 February 2000, he suffered an overdose requiring ICU admission. Despite this critical incident, 20 days later he obtained heroin from outside the hospital and was found intoxicated on the ward evening of 25 February. He died the following morning with a post-mortem olanzapine level of 0.58mg/L—significantly elevated above therapeutic levels (0.01-0.03mg/L). The coroner could not definitively establish cause of death but noted probable drug interactions (olanzapine with fluvoxamine and valproate). Key clinical lessons: detained patients require heightened security and supervision; medication interactions warrant clear warnings; there was inadequate detection of his obvious intoxication and unsupervised access to drugs despite a recent life-threatening overdose.
AI-generated summary and tagging — may contain inaccuracies; refer to original finding for legal purposes.
Specialties
Error types
Contributing factors
- Elevated olanzapine blood level (0.58mg/L) likely potentiated by concurrent fluvoxamine and sodium valproate
- Possible concurrent heroin use (morphine detected at 0.03mg/L)
- Inadequate supervision of detained patient with history of drug-seeking behaviour
- Failure to detect patient intoxication on evening of 25 February despite obvious clinical signs
- Unsupervised access to hospital grounds permitting contact with external drug sources
- Non-compliance or inconsistent medication adherence
- Potential post-mortem drug redistribution effects
Coroner's recommendations
- Manufacturers of olanzapine and fluvoxamine should review product information to provide much clearer warning to clinicians about the interaction between these drugs and that their co-prescription is not recommended
- The product information for olanzapine should explicitly warn of the significant interaction with fluvoxamine, not just in 'fine print'
Full text
Related cases
Source and disclaimer
This page reproduces or summarises information from publicly available findings published by Australian coroners' courts. Coronial is an independent educational resource and is not affiliated with, endorsed by, or acting on behalf of any coronial court or government body.
Content may be incomplete, reformatted, or summarised. All court orders for redaction and non-publication are respected; documents with technically defective redaction have been excluded from the database entirely. Always refer to the original court publication for the authoritative record.
Copyright in original materials remains with the relevant government jurisdiction. AI-generated summaries and tagging are for educational purposes only, may contain inaccuracies, and must not be treated as legal documents. We welcome feedback for correction —